PorMedTec
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
PorMedTec develops medical-grade pig organs for xenotransplantation to solve the global organ shortage crisis.
TransplantationNephrologyCardiologyHepatologyEndocrinology
Technology Platform
Medical-grade DPF (Designated Pathogen-Free) pig production using somatic cell cloning and specialized breeding techniques to create organs for xenotransplantation with reduced immunological rejection risks.
Opportunities
Massive unmet need with global organ transplant demand exceeding supply by 10x, particularly severe in Japan where kidney transplant wait times exceed 14 years, creating potential for first-mover advantage in Asian xenotransplantation markets.
Risk Factors
High regulatory hurdles for xenotransplantation, significant immunological challenges including hyperacute and chronic rejection, zoonotic disease transmission concerns, and ethical considerations around animal use.
Competitive Landscape
Competes with eGenesis, United Therapeutics/Revivicor, and Makana Therapeutics in xenotransplantation; differentiates through focus on medical-grade DPF pig production infrastructure and Asian market positioning.